Founded in 2017 at the World Economic Forum, Access Accelerated is a collective of leading biopharmaceutical and life science companies working to advance action for NCDs. Fueled by the belief that all people should have access to quality NCD prevention, treatment and care, we implement scalable solutions through partnerships that address barriers to NCD care. As an industry-led initiative, Access Accelerated provides a structure for cooperation across sectors and actors, including implementors, decision-makers and financers. Together, we support our strategic partner, the World Bank, to increase access to NCD services in low- and middle-income countries. Our multi-disciplinary expertise spans a wide range of therapeutic areas and our collective insights stem from more than 100 public health programs that we operate around the world. Underlying our work is our commitment to supporting the United Nations Sustainable Development Goals (SDGs), in particular, the target to reduce premature deaths from NCDs by one-third by 2030 (3.4) and the target to strengthen the means of implementation and global partnership (17). Access Accelerated is headquartered in Geneva, Switzerland

The Access Accelerated Steering Committee is the primary strategic decision-making body and consists of one representative from each member company. Through consensus, the Steering Committee guides the overall vision and direction of Access Accelerated with guidance from member company CEOs.

Based in Geneva, the Access Accelerated Secretariat serves as the managing body implementing programs and activities. Executing on operational decisions and driving workstreams, the Secretariat plays a crucial role in bringing the initiative's vision to life.